Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2015-10-09

Clinical Trial Update: Study of Secukinumab in Patients With Newly-diagnosed Type 1 Diabetes Mellitus [Phase 2]

View source ↗

Summary

A Phase 2 study of Secukinumab in newly diagnosed Type 1 Diabetes Mellitus was terminated, with results subsequently posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Secukinumab (secukinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Type 1 Diabetes Mellitus | Phase 2 | Status: TERMINATED | Results posted: 2015-10-09